J&J Drops Two Lymphoma CAR-Ts, Citing Portfolio Priorities, Treatment Landscape
The company said it would discontinue development of prizlo-cel and JNJ-9530, which it licensed in 2023, even though prizlo-cel has demonstrated strong efficacy in LBCL.
Scrip - May 1, 2026

IQVIA Consumer Health: Rx-To-OTC Switch ‘Back On The Agenda’ In Europe
IQVIA Consumer Health argues that mounting pressure on European health systems is driving a new era of Rx-to-OTC switch, and that smarter use of real-world evidence and an expanded pharmacist role could unlock the next wave of reclassifications.
HBW Insight - May 1, 2026

ResMed Says GLP-1s Won’t Affect Business As Earnings Beat Expectations
Company announces acquisition of restless-leg syndrome company Noctrix as it highlights synergy in neurology.
Medtech Insight - May 1, 2026

Robotic Mastectomy Comparable To Open Surgery, But Ergonomics May Shift Surgeon Preference
ASBrS 2026 data showed that robotic nipple-sparing mastectomy with the da Vinci SP system matched open surgery on safety and patient-reported outcomes, but surgeon ergonomics may differentiate the two.
Medtech Insight - May 1, 2026

Summit’s Bet On Early Success For Ivonescimab Falls Flat
A bid to fast track the PD-1xVEGF candidate in non-small cell lung cancer has failed – and raises the stakes for partner Akeso’s upcoming ASCO presentation.
Scrip - May 1, 2026

UniQure Targets UK Okay For Huntington’s Gene Therapy After FDA Clashes
The firm is looking to file AMT-130 with the MHRA with the same data package that has been rejected by the US regulator.
Scrip - May 1, 2026

Scrip M&A Podcast: What Can We Infer From The First Quarter’s Late Deal Flurry
With Cooley LLP partners Kevin Cooper and Bill Roegge, Scrip’s Joseph Haas discussed the current state of biopharma M&A, how smaller companies can negotiate a solid buyout and whether competitive bids may become more common.
Scrip - May 1, 2026

Indoco Refocuses With ‘Non-Core’ India And Africa Divestment
Indoco Remedies is divesting its ophthalmic division across India and Africa for INR1.1bn, sharpening its focus on core therapies, as Sunways scales its ophthalmology platform through a strategically aligned bolt-on acquisition.
Generics Bulletin - May 1, 2026

Henlius-Organon Wins EU’s First Perjeta Biosimilar Approval
The approvals of the Poherdy (pertuzumab) biosimilar on two continents cement Henlius and Organon as the team to beat in the pertuzumab biosimilar race – whenever that race officially starts.
Generics Bulletin - May 1, 2026

Teva Meets European Ambition On Olanzapine
Teva is continuing to advance its long-acting olanzapine, with a filing now complete in Europe. The firm’s generics sales slumped in Q1 due to lenalidomide but biosimilars growth and pipeline expansion signal longer-term upside.
Generics Bulletin - May 1, 2026

What’s Next? Five Things To Look Out For In May
Generics Bulletin previews the most noteworthy and anticipated events for May 2026.
Generics Bulletin - May 1, 2026

Podcast: Carna Health On Closing the Gap in CKD Prevention
Salvatore Viscomi, CEO and co-founder of Carna Health, discussed the company's pivotal work to combat the global crisis of chronic kidney disease (CKD).
In Vivo - May 1, 2026

Chugai Focuses On Innovation Capabilities As Its Logs Solid Q1
After a quarter which saw good growth at home and abroad, Chugai looks to the global progress of orforglipron through Lilly and stresses an investment focus on R&D and late-stage assets.
Scrip - May 1, 2026

US Consumer Health News Digest: Business, Regulation, Science
HBW Insight notes recent news from across the US consumer health industry and marketplace in our latest weekly digest.
HBW Insight - May 1, 2026

Axoft Raises $55M To Advance Brain-Computer Interface Toward FDA Approval In 2027
Cambridge, Massachusetts-based Axoft closed a $55m Series A funding round to expand global clinical trials and pursue FDA clearance for its ultra-soft brain-computer interface designed to detect consciousness in coma patients.
Medtech Insight - May 1, 2026